The aim of the current study was, therefore, to use immunohistochemical approaches to assess the expression of all three members of the Trx system in four different brain tumour cohorts, to evaluate their associations with clinicopathological and survival criteria and, additionally, to compare levels of expression across different tumour regions/types/grades. The gene discussed is TXN; the disease is neoplasm.